Agree Didak, the director selldown and chairman commentary late last year combined with the lower outlook guidance this year doesn't sit well with investors atm. But they still delivered 35% earnings growth and expecting very strong growth in FY19. This is in complete contrast to other companies where management sold down which was shortly Followed by an earnings downgrade. Big difference between the two in my book.
- Forums
- ASX - By Stock
- Ann: Half Yearly Report and Accounts
Agree Didak, the director selldown and chairman commentary late...
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EML (ASX) to my watchlist
(20min delay)
|
|||||
Last
67.0¢ |
Change
-0.040(5.63%) |
Mkt cap ! $253.4M |
Open | High | Low | Value | Volume |
70.0¢ | 70.0¢ | 66.5¢ | $1.111M | 1.635M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 109155 | 66.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
67.0¢ | 4999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 109155 | 0.665 |
10 | 178848 | 0.660 |
5 | 91592 | 0.655 |
11 | 114407 | 0.650 |
1 | 8646 | 0.645 |
Price($) | Vol. | No. |
---|---|---|
0.670 | 4999 | 1 |
0.675 | 8646 | 1 |
0.680 | 32439 | 3 |
0.685 | 9826 | 2 |
0.690 | 28646 | 2 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
EML (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online